Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NANP | Q8TBE9 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15343657 | 1.00 | NANP (0.38) | NANPTDP1 | |
| SCHEMBL29259492 | 1.00 | NANP (0.38) | NANPTDP1 | |
| SCHEMBL12600802 | 1.00 | NANP (0.38) | NANPTDP1 | |
| SCHEMBL15343918 | 1.00 | NANP (0.38) | NANPTDP1 | |
| SCHEMBL126553 | 1.00 | NANP (0.38) | NANPTDP1 | |
| SCHEMBL24630164 | 1.00 | NANP (0.38) | NANPTDP1 | |
| SCHEMBL15279194 | 0.92 | NANP (0.36) | NANPTDP1 | |
| SCHEMBL25426120 | 0.92 | NANP (0.36) | NANPTDP1 | |
| SCHEMBL20495386 | 0.92 | NANP (0.36) | NANPTDP1 | |
| SCHEMBL25426117 | 0.92 | NANP (0.36) | NANPTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120053420-A | Application of compound in preparation of medicines for treating liver cancer | 复旦大学附属中山医院 | 2025-05-30 | — | — | CN | claimed |
| CN-118178673-B | Sialic acid ester cyclodextrin inclusion compound and preparation method and application thereof | 铭畅生物医药南通有限公司 | 2024-11-05 | — | — | CN | claimed |
| CN-118178673-A | Sialic acid ester cyclodextrin inclusion compound and preparation method and application thereof | 铭畅生物医药南通有限公司 | 2024-06-14 | — | — | CN | claimed |
| US-20250313574-A1 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2025-10-09 | — | — | US | disclosed |
| CN-120053420-A | Application of compound in preparation of medicines for treating liver cancer | 复旦大学附属中山医院 | 2025-05-30 | — | — | CN | disclosed |
| CN-120053420-A | Application of compound in preparation of medicines for treating liver cancer | 复旦大学附属中山医院 | 2025-05-30 | — | — | CN | disclosed |
| CN-118178673-B | Sialic acid ester cyclodextrin inclusion compound and preparation method and application thereof | 铭畅生物医药南通有限公司 | 2024-11-05 | — | — | CN | disclosed |
| CN-118178673-A | Sialic acid ester cyclodextrin inclusion compound and preparation method and application thereof | 铭畅生物医药南通有限公司 | 2024-06-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250313574-A1 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | NEU1, NEU2, NEU4 | NANP 63/4885TDP1 2619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.